Dr. Reddy's Launches First-to-Market Generic of Extra-Strength Pataday® in U.S. OTC Market
RDY is trading near its 52-week low of $12.26 (8.5% above the low).
Summary
Dr. Reddy's Laboratories announced the first-to-market U.S. launch of a generic equivalent to Extra-Strength Pataday® Once Daily Relief, expanding its OTC eye-care portfolio.
Key Events · Product Development and Regulatory · RDY
-
First-to-Market Generic Launch
Dr. Reddy's launched Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the generic equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.
-
Market Opportunity
The branded Pataday® product had U.S. sales of approximately $69.9 million in the latest 52-week period, representing a significant market for the new generic.
-
Portfolio Expansion
This launch strengthens Dr. Reddy's existing OTC eye-care portfolio, which already includes 0.2% and 0.1% strengths of Olopatadine Hydrochloride Ophthalmic Solution.
Analysis · RDY · Life Sciences
This launch expands Dr. Reddy's presence in the U.S. over-the-counter eye-care market with a key generic product. Being the first to market for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% provides a significant competitive advantage, allowing the company to capture a substantial share of the approximately $69.9 million annual sales market for the branded product. This demonstrates Dr. Reddy's strong capabilities in generic product development and commercialization.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 30% of the 1759 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RDY was trading at $13.30 on NYSE in the Life Sciences sector, with a market capitalization of approximately $11B. The 52-week trading range was $12.26 to $16.17. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.